Interestingly, low levels of LRP2 were associated with poor patient outcome in seven of the eight cancer types that express the highest levels of LRP2 on average (Figure 4, Table S2), including kidney renal clear cell carcinoma (KIRC) (HR = 0.91, p < 0.001), kidney renal papillary cell carcinoma (KIRP) (HR = 0.88, p < 0.01), mesothelioma (MESO) (HR = 0.87, p < 0.01), thyroid carcinoma (THCA) (HR = 0.82, p < 0.05), breast cancer (METABRIC) (HR = 0.90, p < 0.0001), lung adenocarcinoma (LUAD) (HR = 0.95, p < 0.05), and skin cutaneous melanoma (SKCM) (HR = 0.95, p < 0.05). This evidence concerns the gene LRP2 and thyroid gland carcinoma.